Development and evaluation of buspirone hydrochloride nanoparticle temperature-sensitive gel for treating generalized anxiety disorder

Abstract

Generalized Anxiety Disorder (GAD) is a prevalent anxiety disorder that significantly impairs patients' quality of life. Conventional treatments for GAD often cause adverse reactions, and Buspirone hydrochloride (BUS), a newer anti-anxiety medication, suffers from low bioavailability, thereby limiting its therapeutic effectiveness. Therefore, it is essential to develop a formulation with improved safety and enhanced bioavailability. To address this need, buspirone hydrochloride nanoparticle temperature-sensitive gels (BUS-NPs-GEL) are designed to undergo a temperature-triggered sol-gel transition in the nasal cavity during administration, facilitating sustained release and extended retention of buspirone hydrochloride-chitosan nanoparticles (BUS-NPs). This mechanism facilitates the extended delivery of BUS to the target site, thereby improving therapeutic outcomes. Collectively, the development of buspirone hydrochloride nanoparticle temperature-sensitive gels represents a promising and innovative strategy for the treatment of GAD.